Andrés Salmerón

1.0k citations

19 papers · 786 indexed · h-index 9

Co-authors: Steven C. Ley Tahir Ahmad Radha P. Narsimhan Darryl Pappin Graeme W. Carlile José M. Lora Srimoyee Ghosh Barbara M. Bryant
Topics: CAR-T cell therapy research (8 papers)Cancer Research and Treatments (5 papers)Cancer Immunotherapy and Biomarkers (5 papers)
Cited by: Cancer Research Immunology Oncology
Journals: Journal of Biological Chemistry The Journal of Experimental MedicineSHILAP Revista de lepidopterología
Partner nations: United States United Kingdom Tanzania

In The Last Decade

Andrés Salmerón

18 papers receiving 760 citations

Peers

Countries citing papers authored by Andrés Salmerón

Since Specialization

Citations

This map shows the geographic impact of Andrés Salmerón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrés Salmerón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrés Salmerón more than expected).

Fields of papers citing papers by Andrés Salmerón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrés Salmerón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrés Salmerón. The network helps show where Andrés Salmerón may publish in the future.

Co-authorship network of co-authors of Andrés Salmerón

This figure shows the co-authorship network connecting the top 25 collaborators of Andrés Salmerón. A scholar is included among the top collaborators of Andrés Salmerón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrés Salmerón. Andrés Salmerón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Abstract 4074: Discovery of WTX-518, an IL-18 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models 2024 ·Cancer Research ·Kristin Morris,(unknown),(unknown),Daniel J. Hicklin,(unknown),(unknown),Christopher J. Nirschl,Andrés Salmerón,Cynthia Seidel‐Dugan,(unknown),(unknown),William M. Winston	2
2	Abstract 4078: WTX-712, a conditionally active IL-21 INDUKINETM molecule, induces a strong anti-tumor phenotype through a differentiated mechanism 2024 ·Cancer Research ·Jenna M. Sullivan,(unknown),(unknown),(unknown),(unknown),Daniel J. Hicklin,(unknown),(unknown),(unknown),(unknown),Andrés Salmerón	1
3	Abstract 1829: Generation of IL-21 INDUKINETM molecules for the treatment of cancer 2023 ·Cancer Research ·Jenna M. Sullivan,(unknown),(unknown),(unknown),Daniel J. Hicklin,(unknown),(unknown),(unknown),(unknown),(unknown),Andrés Salmerón	1
4	mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity 2023 ·Cancer Immunology Research ·Christopher J. Nirschl,(unknown),(unknown),Connor J. Dwyer,Daniel J. Hicklin,(unknown),Cynthia Seidel‐Dugan,(unknown),(unknown),Jenna M. Sullivan,William M. Winston,Andrés Salmerón	8
5	Abstract 2054: WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives anti-tumor immunity by activating tumor infiltrating CD8+ T cells 2022 ·Cancer Research ·Christopher J. Nirschl,(unknown),Daniel J. Hicklin,Nesreen S. Ismail,Kristin Morris,Andrés Salmerón,Cynthia Seidel‐Dugan,Philipp Steiner,(unknown),Jenna M. Sullivan,William M. Winston	0
6	Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody 2021 ·Cancer Treatment and Research Communications ·Kenna Shirasuna,Gerald Koelsch,Cynthia Seidel‐Dugan,Andrés Salmerón,Philipp Steiner,William M. Winston,(unknown),Christopher J. Nirschl,(unknown),(unknown),(unknown),(unknown),Masahiro Takeuchi,Daniel J. Hicklin,Taku Yoshida	10
7	723 WTX-613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models 2021 ·SHILAP Revista de lepidopterología ·Ethika Tyagi,(unknown),(unknown),Dan Hicklin,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Andrés Salmerón,(unknown),Philipp Steiner,(unknown),Jenna M. Sullivan,William M. Winston	3
8	Abstract 1716: WTX-330, a conditionally activated IL-12 INDUKINE, releases IL-12 selectively in the tumor microenvironment to activate anti-tumor immune responses and induce regressions in mouse tumor models 2021 ·Cancer Research ·Philipp Steiner,(unknown),Dan Hicklin,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Andrés Salmerón,(unknown),(unknown),Jenna M. Sullivan,William M. Winston	4
9	Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates 2021 ·Blood ·Philipp Steiner,(unknown),(unknown),Daniel J. Hicklin,Randi Isaacs,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Andrés Salmerón,(unknown),(unknown),Jenna M. Sullivan,Ethika Tyagi,William M. Winston	9
10	715 WTX-330 is an IL-12 pro-drug that is conditionally activated within the tumor microenvironment and induces regressions in mouse tumor models 2021 ·SHILAP Revista de lepidopterología ·Kristin Morris,(unknown),Daniel J. Hicklin,Nesreen S. Ismail,Christopher J. Nirschl,Andrés Salmerón,Philipp Steiner,(unknown),Jenna M. Sullivan,William M. Winston	2
11	Abstract 1723: WTX-124 is an IL-2 pro-drug conditionally activated in tumors and able to induce complete regressions in mouse tumor models 2021 ·Cancer Research ·Andrés Salmerón,(unknown),Daniel J. Hicklin,Nesreen S. Ismail,Kristin Morris,Christopher J. Nirschl,Cynthia Seidel‐Dugan,Philipp Steiner,(unknown),Jenna M. Sullivan,William M. Winston	1
12	718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models 2021 ·SHILAP Revista de lepidopterología ·Christopher J. Nirschl,(unknown),Daniel J. Hicklin,Nesreen S. Ismail,Kristin Morris,Andrés Salmerón,(unknown),Philipp Steiner,(unknown),Jenna M. Sullivan,William M. Winston	3
13	Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease 2017 ·Scientific Reports ·Michelle L. Manni,Sivanarayana Mandalapu,Andrés Salmerón,José M. Lora,Jay K. Kolls,John F. Alcorn	13
14	BET bromodomain inhibition suppresses TH17-mediated pathology 2013 ·The Journal of Experimental Medicine ·Deanna A. Mele,Andrés Salmerón,Srimoyee Ghosh,Hon-Ren Huang,Barbara M. Bryant,José M. Lora	174
15	Cot/Tpl-2 Protein Kinase as a Target for the Treatment of Inflammatory Disease 2009 ·Current Topics in Medicinal Chemistry ·(unknown),Andrés Salmerón	40
16	Identification of a selective thieno[2,3-c]pyridine inhibitor of COT kinase and TNF-α production 2009 ·Bioorganic & Medicinal Chemistry Letters ·Kevin P. Cusack,Hamish Allen,(unknown),Anca Clabbers,Richard J. Dixon,(unknown),Michael Friedman,Y. Gaumont,(unknown),(unknown),(unknown),(unknown),Yong Jia,Maria D. Moskey,Christopher Quinn,Andrés Salmerón,Christine K. Thomas,Grier A. Wallace,Neil Wishart,Zhengtian Yu	22
17	βTrCP-Mediated Proteolysis of NF-κB1 p105 Requires Phosphorylation of p105 Serines 927 and 932 2002 ·Molecular and Cellular Biology ·Valérie Lang,Julia Janzen,(unknown),Yasmina Soneji,Sören Beinke,Andrés Salmerón,Hamish Allen,Ronald T. Hay,Yinon Ben‐Neriah,Steven C. Ley	116
18	Direct Phosphorylation of NF-κB1 p105 by the IκB Kinase Complex on Serine 927 Is Essential for Signal-induced p105 Proteolysis 2001 ·Journal of Biological Chemistry ·Andrés Salmerón,Julia Janzen,Yasmina Soneji,Nancy J. Bump,Joanne Kamens,Hamish Allen,Steven C. Ley	114
19	Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. 1996 ·The EMBO Journal ·Andrés Salmerón,Tahir Ahmad,Graeme W. Carlile,Darryl Pappin,Radha P. Narsimhan,Steven C. Ley	263

About Andrés Salmerón

Andrés Salmerón is a scholar working on Oncology, Biotechnology and Immunology, having authored 19 papers that have together received 786 indexed citations. Recurring topics across this work include CAR-T cell therapy research (8 papers), Cancer Research and Treatments (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Cancer Research (253 citations), Immunology (315 citations) and Oncology (237 citations). Andrés Salmerón has collaborated with scholars based in United States, United Kingdom and Tanzania. Frequent co-authors include Steven C. Ley, Tahir Ahmad, Radha P. Narsimhan, Darryl Pappin, Graeme W. Carlile, José M. Lora, Srimoyee Ghosh, Barbara M. Bryant, Hon-Ren Huang and Deanna A. Mele. Their work appears in journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact